BioLineRx Ltd. (BLRX) Receives New Coverage from Analysts at Oppenheimer Holdings, Inc.
Oppenheimer Holdings, Inc. began coverage on shares of BioLineRx Ltd. (NASDAQ:BLRX) in a report released on Friday. The firm set an “outperform” rating and a $3.00 price target on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price target would indicate a potential upside of 175.23% from the company’s previous close.
A number of other equities analysts have also recently issued reports on the company. Roth Capital assumed coverage on BioLineRx in a report on Thursday. They set a “buy” rating and a $3.00 price objective for the company. Zacks Investment Research upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Maxim Group set a $3.00 price objective on BioLineRx and gave the company a “buy” rating in a report on Monday, July 10th. Finally, HC Wainwright set a $4.00 price objective on BioLineRx and gave the company a “buy” rating in a report on Saturday, June 3rd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. BioLineRx has an average rating of “Buy” and a consensus target price of $2.59.
Shares of BioLineRx (NASDAQ:BLRX) traded up 3.81% during mid-day trading on Friday, reaching $1.09. The company had a trading volume of 1,384,595 shares. The firm has a 50-day moving average price of $0.90 and a 200-day moving average price of $0.96. The stock’s market capitalization is $67.34 million. BioLineRx has a 1-year low of $0.75 and a 1-year high of $1.42.
BioLineRx (NASDAQ:BLRX) last released its earnings results on Thursday, May 25th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.03. Equities analysts expect that BioLineRx will post ($0.24) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “BioLineRx Ltd. (BLRX) Receives New Coverage from Analysts at Oppenheimer Holdings, Inc.” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/06/biolinerx-ltd-blrx-receives-new-coverage-from-analysts-at-oppenheimer-holdings-inc.html.
Institutional investors have recently bought and sold shares of the stock. Sabby Management LLC acquired a new position in BioLineRx during the first quarter worth about $3,018,000. KCG Holdings Inc. boosted its position in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the last quarter. Renaissance Technologies LLC acquired a new position in BioLineRx during the first quarter worth about $126,000. Citadel Advisors LLC boosted its position in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the last quarter. Finally, Benchmark Capital Advisors boosted its position in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the last quarter. Institutional investors own 38.01% of the company’s stock.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.